These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26913729)

  • 21. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves' disease relapse.
    Ueda M; Inaba M; Kumeda Y; Nagasaki T; Hiura Y; Tahara H; Onoda N; Ishikawa T; Nishizawa Y
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):657-62. PubMed ID: 16343100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doppler ultrasonography in predicting relapse of hyperthyroidism in Graves' disease.
    Varsamidis K; Varsamidou E; Mavropoulos G
    Acta Radiol; 2000 Jan; 41(1):45-8. PubMed ID: 10665869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ultrasonographic evaluation of thyroid tissue perfusion in patients with Graves-Basedow disease as preparation for surgery].
    Rogula T; Cichoń S
    Folia Med Cracov; 2000; 41(3-4):121-9. PubMed ID: 11339007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mean peak systolic velocity of the superior thyroid artery is correlated with radioactive iodine uptake in untreated thyrotoxicosis.
    Chen L; Zhao X; Liu H; Wang Y; Li L; Lu B; Li Y; Hu R
    J Int Med Res; 2012; 40(2):640-7. PubMed ID: 22613425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The characteristics of two-dimensional and color Doppler ultrasonography in Graves' disease].
    Li J; Zhang J; Bai Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Jun; 16(3):170-4. PubMed ID: 7805159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascularity of the thyroid in Graves' disease.
    Ozaki O; Mishima I; Cho T
    Yonago Acta Med; 1972 Feb; 16(1):1-4. PubMed ID: 4679296
    [No Abstract]   [Full Text] [Related]  

  • 28. Thyroid blood flow and uptake of technetium-99m pertechnetate in Graves' disease.
    Sekulić V; Rajić M; Vlajković M; Ilić S; Bogićević M; Antić S; Dimić D
    Hell J Nucl Med; 2006; 9(3):173-6. PubMed ID: 17160158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow.
    Ide A; Amino N; Kang S; Yoshioka W; Kudo T; Nishihara E; Ito M; Nakamura H; Miyauchi A
    Thyroid; 2014 Jun; 24(6):1027-31. PubMed ID: 24400892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of preoperative iodine in patients with Graves' disease controlled with antithyroid drugs and thyroxine.
    Kaur S; Parr JH; Ramsay ID; Hennebry TM; Jarvis KJ; Lester E
    Ann R Coll Surg Engl; 1988 May; 70(3):123-7. PubMed ID: 2457351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction in the suppressor-inducer T cell subset and increase in the helper T cell subset in thyroid tissue from patients with Graves' disease.
    Ishikawa N; Eguchi K; Otsubo T; Ueki Y; Fukuda T; Tezuka H; Matsunaga M; Kawabe Y; Shimomura C; Izumi M
    J Clin Endocrinol Metab; 1987 Jul; 65(1):17-23. PubMed ID: 2953751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A study using FRTL-5 cell for detecting thyroid stimulating antibody activity in serum in patients with Graves disease].
    Li J; Gao H; Jin SX
    Zhonghua Nei Ke Za Zhi; 1991 Jul; 30(7):392-4, 454. PubMed ID: 1684315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subclinical Graves' disease as a cause of subnormal TSH levels in euthyroid subjects.
    Kasagi K; Takeuchi R; Misaki T; Kousaka T; Miyamoto S; Iida Y; Konishi J
    J Endocrinol Invest; 1997 Apr; 20(4):183-8. PubMed ID: 9211123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T3-release from autonomously functioning thyroid nodules in vitro.
    Poertl S; Kirner J; Saller B; Mann K; Hoermann R
    Exp Clin Endocrinol Diabetes; 1998; 106(6):489-93. PubMed ID: 10079030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased micrococcal nuclease sensitivity and/or solubility in nuclei from Graves' disease thyroid tissue.
    Inaba M; Hamada N; Morii H; Ohno M; Yamakawa J; No J; Mimura T; Ito K; Yukioka M
    J Clin Endocrinol Metab; 1984 Sep; 59(3):427-31. PubMed ID: 6547727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Color Doppler sonography in Graves' disease: value in assessing activity of disease and predicting outcome.
    Castagnone D; Rivolta R; Rescalli S; Baldini MI; Tozzi R; Cantalamessa L
    AJR Am J Roentgenol; 1996 Jan; 166(1):203-7. PubMed ID: 8571877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid arterial embolization to treat Graves' disease.
    Zhao W; Gao BL; Yang HY; Li H; Song DP; Xiang ST; Shen J
    Acta Radiol; 2007 Mar; 48(2):186-92. PubMed ID: 17354140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of anti-thyroid drugs in euthyroid pregnant women with previous Graves' disease.
    McNab T; Ginsberg J
    Clin Invest Med; 2005 Jun; 28(3):127-31. PubMed ID: 16021986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid Doppler ultrasonography and resistive index in the evaluation of the need for ablative or antithyroid drug therapy in Graves' hyperthyroidism.
    Wang CY; Chang TC
    J Formos Med Assoc; 2001 Nov; 100(11):753-7. PubMed ID: 11802534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.